AIMS: Benidipine, an L-/T-type calcium channel blocker, dilates renal efferent and afferent arterioles and reduces glomerular pressure; therefore, it may exert renoprotective effects. We conducted an open-labeled randomized trial to compare the effects of benidipine with cilnidipine in hypertensive patients with chronic kidney disease (CKD). METHODS: The patients who were already being treated with angiotensin receptor blockers (ARBs) received one of the following treatment regimens: benidipine at a dose of 2 mg/day that was increased up to a dose of 8 mg/day (benidipine group; n=118) or cilnidipine at a dose of 5 mg/day that was increased up to a dose of 20 mg/day (cilnidipine group; n=115). RESULTS: After 12 months of treatment, we observed a significant and comparable reduction in the systolic and diastolic blood pressure in both groups. The urinary protein:creatinine ratio was significantly decreased in both groups after 3 months of treatment and thereafter; however, the difference between both groups was not significant after 12 months of treatment. Benidipine exerted an antiproteinuric effect to a greater extent than cilnidipine in patients with diabetes. CONCLUSION: The addition of benidipine as well as cilnidipine reduces urinary protein excretion in hypertensive patients with CKD who are already being administered ARBs.
RCT Entities:
AIMS: Benidipine, an L-/T-type calcium channel blocker, dilates renal efferent and afferent arterioles and reduces glomerular pressure; therefore, it may exert renoprotective effects. We conducted an open-labeled randomized trial to compare the effects of benidipine with cilnidipine in hypertensivepatients with chronic kidney disease (CKD). METHODS: The patients who were already being treated with angiotensin receptor blockers (ARBs) received one of the following treatment regimens: benidipine at a dose of 2 mg/day that was increased up to a dose of 8 mg/day (benidipine group; n=118) or cilnidipine at a dose of 5 mg/day that was increased up to a dose of 20 mg/day (cilnidipine group; n=115). RESULTS: After 12 months of treatment, we observed a significant and comparable reduction in the systolic and diastolic blood pressure in both groups. The urinary protein:creatinine ratio was significantly decreased in both groups after 3 months of treatment and thereafter; however, the difference between both groups was not significant after 12 months of treatment. Benidipine exerted an antiproteinuric effect to a greater extent than cilnidipine in patients with diabetes. CONCLUSION: The addition of benidipine as well as cilnidipine reduces urinary protein excretion in hypertensivepatients with CKD who are already being administered ARBs.
Authors: Juan Jose Garcia Sanchez; Juliette Thompson; David A Scott; Rachel Evans; Naveen Rao; Elisabeth Sörstadius; Glen James; Stephen Nolan; Eric T Wittbrodt; Alyshah Abdul Sultan; Bergur V Stefansson; Dan Jackson; Keith R Abrams Journal: Adv Ther Date: 2021-12-08 Impact factor: 3.845
Authors: Muhammad Shahzad Chohan; Mahesh Attimarad; Katharigatta Narayanaswamy Venugopala; Anroop Balachandran Nair; Nagaraja Sreeharsha; Efren Ii Plaza Molina; Ramling Bhagavantrao Kotnal; Sheeba Shafi; Marysheela David; Pottathil Shinu; Abdulrahman Ibrahim Altaysan; Abdulmalek Ahmed Balgoname Journal: Int J Environ Res Public Health Date: 2022-06-14 Impact factor: 4.614